Hypoactive Sexual Desire Disorder
Conditions
Keywords
Hypoactive sexual desire disorder
Brief summary
The purpose of this study is to examine the effect of the testosterone patch, in addition to hormone replacement therapy (HRT), on blood vessel walls, insulin levels and sexual desire.
Detailed description
A woman's ovaries produce the hormone testosterone during her reproductive life but testosterone levels decline with age or when the ovaries are removed. Testosterone has been associated with sexual desire in both men and women. Low testosterone is also believed to cause symptoms of low energy. Thus testosterone is increasingly used in hormone replacement regimens to restore libido and energy in postmenopausal women. In the past testosterone has been administered orally or via subcutaneous implants. Recently testosterone patches have been licensed for treating low libido in postmenopausal women. The testosterone patches deliver a dose of testosterone equivalent to the levels produced by the ovary during a woman's early reproductive years. Oral testosterone can lead to changes to insulin and cholesterol levels which increase the risk of heart disease. On the contrary, testosterone patches may reduce or avoid this risk. To date, trials have predominantly focused on safety data in terms of side effects and basic blood tests. Reviews of the safety of testosterone replacement have emphasised the need for improved safety data, especially in terms of cardiovascular risk. The investigators hypothesis that transdermal testosterone, in addition to HRT, will have no adverse effects on blood vessel walls and insulin levels and that transdermal testosterone significantly improves sexuality and psychological well-being in postmenopausal women. Trial design: The investigators aim to recruit 20 postmenopausal women to wear the testosterone patch for 3 months in addition to their usual hormone replacement therapy. There will be 3 study visits - a pre study visit, week 6 and week 12. At each visit the following procedures will be performed: * Medical history and physical examination * Blood sample - for hormone levels, lipids and insulin levels * Blood vessel stiffness measurements This will be performed using a small ultrasound device at the wrist with blood pressure measured every 5 minutes. * Endothelial function (function of your arterial wall) is measured using a blood pressure cuff on each arm and finger probes on one finger of each hand. The blood pressure cuff is inflated for 5 minutes and is then deflated quickly. The finger probes will record the readings throughout this study. * Sexual satisfaction questionnaire
Interventions
DRUGIntrinsa Transdermal testosterone patch
300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
Sponsors
Royal Brompton & Harefield NHS Foundation Trust
Chelsea and Westminster NHS Foundation Trust
Imperial College Healthcare NHS Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* healthy postmenopausal women * 45 to 70 years of age * on HRT and willing to continue the same HRT regimen for the next 6 months * are in a stable relationship which was started at least 6 months ago * continue on any concomitant medications without any change during the study * give informed consent.
Exclusion criteria
* have dyspareunia * have received testosterone implants within the last 12 months or other androgen therapy within the last 6 months * have received any medications which may interfere with the study (SSRI, anti-androgens, PDE5 inhibitors, DHEA, SERMS) * have a significant psychiatric disorder * have a history of breast cancer * have diabetes, thromboembolic disorders, cardiovascular disease, any condition affecting carbohydrate metabolism, uncontrolled hypertension and uncontrolled hyperlipidaemia * are on tibolone (due to its androgenic effect).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Arterial Compliance - Augmentation Index | 12 weeks from baseline | Peripheral pressure waveforms were captured using radial artery application tonometry via the SphygmoCor apparatus (AtCor Medical Ltd., Sydney, Australia; software version 8.0). The central (ascending aortic) pressure waveform was then derived from an averaged peripheral waveform using a validated, transfer function. The augmentation index (AIx), which gives a composite measure of wave reflection and systemic arterial stiffness can then be calculated by analysis of the central waveform. Aix was defined as the difference between the first and second systolic peaks of the central pressure waveform, expressed as a percentage of the central pulse pressure. |
| Endothelial Function | 12 weeks from baseline | Reactive Hyperaemia Index (RHI) was calculated automatically by the EndoPAT 2000 computer algorithm from the ratio of pulse wave amplitude before and after ischemia, compared to the control arm. Official reference values do not exist however a lower RHI (\<2.0) is usually considered indicative of endothelial dysfunction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Insulin Resistance - HOMA-IR | 12 weeks from baseline | Blood samples were taken for fasting glucose and insulin levels. From these results, insulin resistance was then estimated using the updated homeostasis model assessment method for insulin resistance (HOMA-IR) computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Typically a cutoff of HOMA-IR for identifying those with insulin resistance is 2.5. |
| Libido - B-PFSF Score | 12 weeks from baseline | Libido was assessed at each visit using the Brief profile of female sexual function (BPFSF), a validated self-administered questionnaire for identifying Hypoactive Sexual Desire Disorder (HSDD). The BPFSF is based on 7 questions. Each question is scored on a 6-point scale from 'always' to 'never'. A total score is total score ranging from 0 to 35. Previous studies have identified a score of less than 20 as suggestive of HSDD. |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Testosterone Testosterone transdermal patch 300micrograms, twice weekly for 12 weeks
Intrinsa Transdermal testosterone patch: 300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks | 21 |
| Total | 21 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Testosterone |
|---|---|
| Age, Continuous | 53.0 years STANDARD_DEVIATION 6.7 |
| Augmentation Index | 24.21 percentage of Arterial stiffness STANDARD_DEVIATION 10.7 |
| Brief Profile of Female Sexual Function (B-PFSF) | 15.3 units on a scale STANDARD_DEVIATION 9.1 |
| Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | 0.78 units on a scale STANDARD_DEVIATION 0.4 |
| Reactive Hyperaemia Index | 1.79 Reactive hyperaemia index STANDARD_DEVIATION 0.36 |
| Region of Enrollment United Kingdom | 21 Participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 21 |
| other Total, other adverse events | 7 / 21 |
| serious Total, serious adverse events | 0 / 21 |
Outcome results
Primary
Arterial Compliance - Augmentation Index
Peripheral pressure waveforms were captured using radial artery application tonometry via the SphygmoCor apparatus (AtCor Medical Ltd., Sydney, Australia; software version 8.0). The central (ascending aortic) pressure waveform was then derived from an averaged peripheral waveform using a validated, transfer function. The augmentation index (AIx), which gives a composite measure of wave reflection and systemic arterial stiffness can then be calculated by analysis of the central waveform. Aix was defined as the difference between the first and second systolic peaks of the central pressure waveform, expressed as a percentage of the central pulse pressure.
Time frame: 12 weeks from baseline
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Testosterone | Arterial Compliance - Augmentation Index | 1.067 percentage of Arterial stiffness |
Primary
Endothelial Function
Reactive Hyperaemia Index (RHI) was calculated automatically by the EndoPAT 2000 computer algorithm from the ratio of pulse wave amplitude before and after ischemia, compared to the control arm. Official reference values do not exist however a lower RHI (\<2.0) is usually considered indicative of endothelial dysfunction.
Time frame: 12 weeks from baseline
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Testosterone | Endothelial Function | 0.06 units on a scale |
Secondary
Insulin Resistance - HOMA-IR
Blood samples were taken for fasting glucose and insulin levels. From these results, insulin resistance was then estimated using the updated homeostasis model assessment method for insulin resistance (HOMA-IR) computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Typically a cutoff of HOMA-IR for identifying those with insulin resistance is 2.5.
Time frame: 12 weeks from baseline
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Testosterone | Insulin Resistance - HOMA-IR | 0.106 units on a scale |
Secondary
Libido - B-PFSF Score
Libido was assessed at each visit using the Brief profile of female sexual function (BPFSF), a validated self-administered questionnaire for identifying Hypoactive Sexual Desire Disorder (HSDD). The BPFSF is based on 7 questions. Each question is scored on a 6-point scale from 'always' to 'never'. A total score is total score ranging from 0 to 35. Previous studies have identified a score of less than 20 as suggestive of HSDD.
Time frame: 12 weeks from baseline
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Testosterone | Libido - B-PFSF Score | 5.05 units on a scale |